Zhong, Allison Y.
Lui, Asona J.
Katz, Matthew S.
Berlin, Alejandro
Kamran, Sophia C.
Kishan, Amar U.
Murthy, Vedang
Nagar, Himanshu
Seible, Daniel
Stish, Bradley J.
Tree, Alison C.
Seibert, Tyler M.
Funding for this research was provided by:
National Institutes of Health (UL1TR001442, NIH/NIBIB K08 EB026503, NIH/NCI U54CA132384, U54CA132379)
American Society for Radiation Oncology
Moores Cancer Center, UC San Diego Health
Prostate Cancer Foundation
Radiological Society of North America
American College of Radiation Oncology
Article History
Received: 9 September 2023
Accepted: 5 November 2023
First Online: 11 November 2023
Declarations
:
: The study was approved by the Institutional Review Board. Participants gave consent to participate electronically.
: Not applicable.
: Dr. Tree declares research funding from Elekta, Varian Medical Systems, Inc., and Accuray. Dr. Tree declares honoraria or travel assistance from Elekta, Accuray, and Janssen. Dr. Lui is a consultant for MIM software. Dr. Katz declares stock ownership with CVS Health, Dr. Reddy's Laboratories, Healthcare Services, Quest Diagnostics, Teladoc Health, Pfizer, Moderna, and Bavarian Nordic. Dr. Murthy declares research funding from Varian Medical Systems, Inc. Dr. Stish declares research funding from Varian Medical Systems, Inc. Dr. Kishan declares research funding from ViewRay, Inc., Janssen, Inc., and Point Biopharmaceuticals, as well as honoraria and/or consulting fees from ViewRay, Inc., Janssen, Inc., Varian Medical Systems, Inc., and Boston Scientific. Dr. Seibert reports honoraria from Varian Medical Systems, Inc. and WebMD; he has an equity interest in CorTechs Labs, Inc. and serves on its Scientific Advisory Board; he has received research grants from GE Healthcare through the University of California San Diego. These companies might potentially benefit from the research results. The terms of this arrangement have been reviewed and approved by the University of California San Diego in accordance with its conflict-of-interest policies.